(S)-methyl 4-(4-(4-(4-((7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)butanamido)-1-methyl-1H-imidazole-2-carboxamido)phenyl)-1-methyl-1H-pyrrole-2-carboxylate | 1383714-47-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-methyl 4-(4-(4-(4-((7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)butanamido)-1-methyl-1H-imidazole-2-carboxamido)phenyl)-1-methyl-1H-pyrrole-2-carboxylate
• 英文别名: (S)-methyl 4-(4-(4-(4-(7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-8-yloxy)butanamido)-1-methyl-1H-imidazole-2-carboxamido)phenyl)-1-methyl-1H-pyrrole-2-carboxylate；KMR-28-39；methyl 4-[4-[[4-[4-[[(6aS)-2-methoxy-11-oxo-6a,7,8,9-tetrahydropyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]butanoylamino]-1-methylimidazole-2-carbonyl]amino]phenyl]-1-methylpyrrole-2-carboxylate
• CAS: 1383714-47-3
• 化学式: C₃₅H₃₇N₇O₇
• 分子量: 667.721
• InChiKey: OUCOTVAZSLYRJX-DEOSSOPVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  49
• 可旋转键数：
  12
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  158
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  1-(4-bromo-1-methyl-1H-pyrrol-2-yl)-2,2,2-trichloroethan-1-one 在 四氢吡咯 、 盐酸 、 4-二甲氨基吡啶 、 四(三苯基膦)钯 、 sodium methylate 、 potassium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三苯基膦 作用下， 以 1,4-二氧六环 、 甲醇 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 5.0h， 生成 (S)-methyl 4-(4-(4-(4-((7-methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)butanamido)-1-methyl-1H-imidazole-2-carboxamido)phenyl)-1-methyl-1H-pyrrole-2-carboxylate
  参考文献：
  名称：

  GC-Targeted C8-Linked Pyrrolobenzodiazepine–Biaryl Conjugates with Femtomolar in Vitro Cytotoxicity and in Vivo Antitumor Activity in Mouse Models

  摘要：

  DNA binding 4-(1-methyl-1H-pyrrol-3-yl)-benzenamine (MPB) building blocks have been developed that span two DNA base pairs with a strong preference for GC-rich DNA. They have been conjugated to a pyrrolo[2,1-c][1,4]benzodiazepine (PBD) molecule to produce C8-linked PBD MPB hybrids that can stabilize GC-rich DNA by up to 13-fold compared to AT-rich DNA. Some have subpicomolar IC50 values in human tumor cell lines and in primary chronic lymphocytic leukemia cells, while being up to 6 orders less cytotoxic in the non-tumor cell line WI38, suggesting that key DNA sequences may be relevant targets in these ultrasensitive cancer cell lines. One conjugate, 7h (KMR-28-39), which has femtomolar activity in the breast cancer cell line MDA-MB-231, has significant dose-dependent antitumor activity in MDA-MB-231 (breast) and MIA PaCa-2 (pancreatic) human tumor xenograft mouse models with insignificant toxicity at therapeutic doses. Preliminary studies suggest that 7h may sterically inhibit interaction of the transcription factor NF-kappa B with its cognate DNA binding sequence.

  DOI：

  10.1021/jm301882a

文献信息

• [EN] PYRROLOBENZODIAZEPINE COMPOUNDS<br/>[FR] COMPOSÉS PYRROLOBENZODIAZÉPINE
  申请人：FEMTOGENIX LTD

  公开号：WO2015166289A1

  公开（公告）日：2015-11-05

  The invention relates to pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) of formula (I) and in particular to PBD dimers linked through the C1 position, and PBD monomers linked through the C1 position to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents. (I) and salts or solvates thereof, wherein: the dotted lines indicates the optional presence of a double bond between C1 and C2 or C2 and C3; R2-R7 are independently selected substituent groups; and either: (i) R8 and R9 together form a double bond; (ii) R8 is H and R9 is OH; or (iii) R8 is H and R9 is ORA and RA is C1-6 alkyl; where R1 has the formula: -X-L-X'-D -X-L-X'- is a linker group and D has the formula (II) or (III): or where the compound is a dimer with each monomer being the same or different and being of formula (I) where the R1 of the first monomer and R'1 or R'6 of the second monomer, or R6 of the first monomer and R'1 of the second monomer, form together a bridge having the formula -X-L-X'- linking the monomers.

  该发明涉及式(I)的吡咯并[2,1-c][1,4]苯二氮杂环己烯（PBDs），特别是通过C1位置连接的PBD二聚体，以及通过C1位置连接到芳基的PBD单体，以及其药用可接受的盐，这些化合物可用作药物，特别是作为抗增殖剂。其中：虚线表示C1和C2或C2和C3之间的双键的可选存在；R2-R7是独立选择的取代基团；且：（i）R8和R9一起形成一个双键；（ii）R8为H且R9为OH；或者（iii）R8为H且R9为ORA，RA为C1-6烷基；其中R1具有以下结构式：-X-L-X'-D -X-L-X'-为一个连接基团，D具有结构式（II）或（III）；或者该化合物是一个二聚体，每个单体相同或不同，具有式（I），其中第一个单体的R1和第二个单体的R'1或R'6，或第一个单体的R6和第二个单体的R'1，共同形成一个具有结构式-X-L-X'-的桥连接单体的桥。
• [EN] PDD AND BPD COMPOUNDS<br/>[FR] COMPOSÉS DDP ET BPD
  申请人：FEMTOGENIX LTD

  公开号：WO2016198869A1

  公开（公告）日：2016-12-15

  The invention relates to pyrridinobenzodiazepines (PDDs) comprising three fused 6-7- 6–membered rings and to benzopyrridodiazecines (BPDs) comprising three fused 6-8- 6–membered rings and, in particular, to PDD or BPD dimers linked together or PDD and BPD monomers linked to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, such as anti-proliferative agents. PDDs and BPDs may be represented by formula (I): and salts or solvates thereof, wherein R2, R4-R6 and R8 are independently selected substituent groups; and either: (i) R9 and R10 together form a double bond; (ii) R9 is H and R10 is OH; or (iii) R9 is H and R10 is ORA and RA is C1-6 alkyl; wherein each of m, n, u and w may be 0 or 1; where (a) the compound is a dimer with each monomer being the same or different and being of formula (I) where one of R1, R2, R3 and R7 of the first monomer and one of R'1, R'2, R3 and R'7 of the second monomer form together a bridge having the formula –X-L-X'- linking the monomers and m + n + u + w = 1; or (b) a dimer and one of R1, R2 and R3 of the first monomer and one of R'1, R'2 and R3 of the second monomer form together a bridge having the formula –X-L-X'- linking the monomers and m = n = u = w = o; or (c) one of R1, R2, R3 and R7 has the formula: –X- L-X'-D or -(CH2)f-O-R14 and m + n + u + w = o or 1; or (d) R7 has the formula: –X-L-X'- D or -(CH2)g-O -15 and m + n + u + w = 1; and X-L-X'- is a linker group and D has the formula (II) or (III):

  该发明涉及到包含三个融合的6-7-6环的吡啶苯二氮杂环己烷（PDDs）以及包含三个融合的6-8-6环的苯基吡啶二氮杂环己烷（BPDs），特别是涉及到连接在一起的PDD或BPD二聚体或连接到芳香基团的PDD和BPD单体，以及其药用可接受盐，这些化合物可用作药物，如抗增殖剂。PDDs和BPDs可以用以下公式（I）表示：以及其盐或溶剂化合物，其中R2、R4-R6和R8是独立选择的取代基团；并且：（i）R9和R10共同形成双键；（ii）R9为H且R10为OH；或（iii）R9为H且R10为ORA，RA为C1-6烷基；其中m、n、u和w中的每个可能为0或1；其中（a）该化合物是一个二聚体，每个单体相同或不同且为公式（I）的其中一个，其中第一个单体的R1、R2、R3和R7中的一个和第二个单体的R'1、R'2、R3和R'7中的一个共同形成具有公式-X-L-X'-的桥连接单体，且m + n + u + w = 1；或（b）一个二聚体，第一个单体的R1、R2和R3中的一个和第二个单体的R'1、R'2和R3中的一个共同形成具有公式-X-L-X'-的桥连接单体，且m = n = u = w = o；或（c）R1、R2、R3和R7中的一个具有以下公式：-X-L-X'-D或-(CH2)f-O-R14，且m + n + u + w = o或1；或（d）R7具有以下公式：-X-L-X'-D或-( )g-O-15，且m + n + u + w = 1；而X-L-X'-是一个连接基团，D具有以下公式（II）或（III）。
• PYRROLOBENZODIAZEPINES
  申请人：SPIROGEN SÀRL

  公开号：US20150133435A1

  公开（公告）日：2015-05-14

  Pyrrolobenzodiazepine (PBDs) having a (1-methyl-1H-pyrrol-3-yl)phenyl based amino residue were found to be highly effective compounds having improved cytotoxicity ad DNA binding properties.

  发现具有基于(1-甲基-1H-吡咯-3-基)苯基氨基残基的吡咯并苯二氮平（PBDs）是高效化合物，具有改善的细胞毒性和DNA结合性能。
• Pyrridinobenzodiazepine and benzopyrridodiazecine compounds
  申请人：FEMTOGENIX LIMITED

  公开号：US10399970B2

  公开（公告）日：2019-09-03

  The invention relates to pyrridinobenzodiazepines (PDDs) comprising three fused 6-7- 6-membered rings and to benzopyrridodiazecines (BPDs) comprising three fused 6-8- 6-membered rings and, in particular, to PDD or BPD dimers linked together or PDD and BPD monomers linked to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, such as anti-proliferative agents. PDDs and BPDs may be represented by formula (I): and salts or solvates thereof, wherein R2, R4-R6 and R8 are independently selected substituent groups; and either: (i) R9 and R10 together form a double bond; (ii) R9 is H and R10 is OH; or (iii) R9 is H and R10 is ORA and RA is C1-6 alkyl; wherein each of m, n, u and w may be 0 or 1; where (a) the compound is a dimer with each monomer being the same or different and being of formula (I) where one of R1, R2, R3 and R7 of the first monomer and one of R′1, R′2, R3 and R′7 of the second monomer form together a bridge having the formula —X-L-X′— linking the monomers and m+n+u+w=1; or (b) a dimer and one of R1, R2 and R3 of the first monomer and one of R′1, R′2 and R3 of the second monomer form together a bridge having the formula —X-L-X′— linking the monomers and m=n=u=w=o; or (c) one of R1, R2, R3 and R7 has the formula: —X-L-X′-D or —(CH2)f-O—R14 and m+n+u+w=o or 1; or (d) R7 has the formula: —X-L-X′— D or —(CH2)g—O—15 and m+n+u+w=1; and X-L-X′— is a linker group and D has the formula (II) or (III).

  本发明涉及由三个融合的6-7-6-元环组成的吡啶-苯并二氮杂卓（PDDs）和由三个融合的6-8-6-元环组成的苯并吡啶-苯并二氮杂卓（BPDs），特别是涉及连接在一起的PDD或BPD二聚体或连接到芳香基团的PDD和BPD单体及其药学上可接受的盐，它们可用作药物，如抗增生剂。PDDs 和 BPDs 可由式（I）表示：及其盐或溶剂，其中 R2、R4-R6 和 R8 是独立选定的取代基团；并且可以是(i) R9 和 R10 一起形成双键；(ii) R9 是 H，R10 是 OH；或 (iii) R9 是 H，R10 是 ORA，RA 是 C1-6 烷基；其中 m、n、u 和 w 各可为 0 或 1；其中(a)化合物是二聚体，每个单体相同或不同，并具有式(I)，其中第一单体的 R1、R2、R3 和 R7 中的一个与第二单体的 R′1、R′2、R3 和 R′7 中的一个共同形成桥，桥式为 -X-L-X′- 连接单体，且 m+n+u+w=1；或 (b) 二聚体和第一单体的 R1、R2 和 R3 中的一个与第二单体的 R′1、R′2 和 R3 中的一个共同形成桥，桥式为 -X-L-X′- 连接单体，且 m=n=u=w=o；或 (c) R1、R2、R3 和 R7 中的一个具有以下式子：-X-L-X′-D或-(CH2)f-O-R14，且m+n+u+w=o或1；或(d)R7的式为-X-L-X′-D或-( )g-O-15且m+n+u+w=1；X-L-X′-是连接基团且D具有式(II)或(III)。
• PYRROLOBENZODIAZEPINE COMPOUNDS
  申请人：FEMTOGENIX LIMITED

  公开号：US20170050971A1

  公开（公告）日：2017-02-23

  The invention relates to pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) of formula (I) and in particular to PBD dimers linked through the C1 position, and PBD monomers linked through the C1 position to aromatic groups, and pharmaceutically acceptable salts thereof, which are useful as medicaments, in particular as anti-proliferative agents. (I) and salts or solvates thereof, wherein: the dotted lines indicates the optional presence of a double bond between C1 and C2 or C2 and C3; R 2 -R 7 are independently selected substituent groups; and either: (i) R 8 and R 9 together form a double bond; (ii) R 8 is H and R 9 is OH; or (iii) R 8 is H and R 9 is OR A and R A is C 1-6 alkyl; where R 1 has the formula: —X-L-X′-D-X-L-X′— is a linker group and D has the formula (II) or (III): or where the compound is a dimer with each monomer being the same or different and being of formula (I) where the R 1 of the first monomer and R′ 1 or R′ 6 of the second monomer, or R 6 of the first monomer and R′ 1 of the second monomer, form together a bridge having the formula —X-L-X′— linking the monomers.